Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | P4HB | P07237 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL477893 | 0.87 | AR (0.49) | ARL3MBTL1MAPTMEN1KMT2A | |
| SCHEMBL1614434 | 0.85 | ALDH1A1 (0.57) | ARSLC22A12MAPTALDH1A1USP2 | |
| SCHEMBL7291041 | 0.85 | AR (0.46) | ARSLC22A12MAPTALDH1A1USP2 | |
| SCHEMBL1613328 | 0.83 | AR (0.45) | ARSLC22A12GAAMCHR1LRRK2 | |
| SCHEMBL5901049 | 0.83 | PARP15 (0.47) | ARSLC22A12MAPTALDH1A1USP2 | |
| SCHEMBL5649740 | 0.83 | TRPV4 (0.57) | L3MBTL1MAPTALDH1A1GAATRPV4 | |
| Hydrochloric Acid SCHEMBL5900904 | 0.82 | PARP15 (0.46) | ARSLC22A12MAPTALDH1A1USP2 | |
| SCHEMBL13851552 | 0.81 | HTR2A (0.43) | ARL3MBTL1SLC22A12MAPTALDH1A1 | |
| SCHEMBL10752784 | 0.80 | GSK3B (0.50) | ARL3MBTL1SLC22A12MAPTMEN1 | |
| Acetonitrile SCHEMBL28828135 | 0.79 | NPC1 (0.55) | MAPTMEN1KMT2AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
| EP-1042316-B1 | INDOLE DERIVATIVES USEFUL A.O. FOR THE TREATMENT OF OSTEOPOROSIS | NIKEM RESEARCH SRL (IT) | 2005-02-09 | — | — | EP | disclosed |
| US-20040235930-A1 | Indole derivatives and their use for the treatment of osteoporosis amongst other applications | FARINA CARLO (IT) | 2004-11-25 | — | — | US | disclosed |
| EP-1212317-B1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | NIKEM RESEARCH SRL (IT) | 2004-09-15 | — | — | EP | disclosed |
| US-6787550-B1 | 4-(5,6-DICHLORO-1H-INDOL-2-YL)-3-ETHOXY-N-(2,2,6,6 -TETRAMETHYLTETRAMETHYLPIPERIDIN-4-YL)-BENZAMIDE | NIKEM RESEARCH S.R.L. (IT) | 2004-09-07 | — | — | US | disclosed |
| US-20040082786-A1 | Piperazine based inhibitors of factor xa | MILENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| EP-1322610-A2 | PIPERAZINE BASED INHIBITORS OF FACTOR Xa | Millennium Pharmaceuticals, Inc. (US) | 2003-07-02 | — | — | EP | disclosed |
| US-6506758-B2 | 4-(5,6-dichloro-1H-indol-2-yl)-N-(1,2,2,6,6-pentamethyl -piperidin-4-yl)benzamide, for example; selective for mammalian osteoclasts, acting to selectively inhibit their bone resorbing activity | SMITHKLINE BEECHAM LABORATOIRES PHARMCEUTIQUES (FR) | 2003-01-14 | — | — | US | disclosed |
| US-20020099080-A1 | Indole derivatives useful A.O. for the treatment of osteoporosis | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES | 2002-07-25 | — | — | US | disclosed |
| EP-1212317-A1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | GlaxoSmithKline S.p.A. (IT) | 2002-06-12 | — | — | EP | disclosed |
| WO-2002026720-A2 | PIPERAZINE BASED INHIBITORS OF FACTOR Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
| EP-1187813-A1 | AZOLYLBENZAMIDES AND ANALOGUES AND THEIR USE FOR TREATING OSTEOPOROSIS | SMITHKLINE BEECHAM PLC (GB) | 2002-03-20 | — | — | EP | disclosed |
| WO-2001002388-A1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | GLAXOSMITHKLINE S.P.A. (IT) | 2001-01-11 | — | — | WO | disclosed |
| WO-2001000587-A1 | AZOLYLBENZAMIDES AND ANALOGUES AND THEIR USE FOR TREATING OSTEOPOROSIS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-01-04 | — | — | WO | disclosed |
| EP-1042316-A1 | INDOLE DERIVATIVES USEFUL A.O. FOR THE TREATMENT OF OSTEOPOROSIS | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999033822-A1 | INDOLE DERIVATIVES USEFUL A.O. FOR THE TREATMENT OF OSTEOPOROSIS | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1999-07-08 | — | — | WO | disclosed |
| EP-0166609-A2 | Aryl derivatives of heterobicyclic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | AR 150/4885L3MBTL1 1534/4885SLC22A12 1154/4885 |
| US-20020099080-A1 | Indole derivatives useful A.O. for the treatment of osteoporosis | SOST, NR3C2, EBP | AR 14/4885L3MBTL1 2820/4885SLC22A12 2302/4885 |
| US-20040082786-A1 | Piperazine based inhibitors of factor xa | TFPI, F11, F12 | AR 4375/4885L3MBTL1 1615/4885SLC22A12 1880/4885 |
| US-20040235930-A1 | Indole derivatives and their use for the treatment of osteoporosis amongst other applications | MALT1, SOST, NFATC1 | AR 1236/4885L3MBTL1 2357/4885SLC22A12 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.